Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
DOI:
https://doi.org/10.2340/sju.v58.5923Keywords:
survival, metastatic bladder cancer, pre-immunotherapy, population-based, chemotherapyAbstract
Before immunotherapy became part of the management of metastatic bladder cancer (mBC), systemic anti-cancer treatment comprised primarily of platinum-based chemotherapy. The objective of this study was to describe the characteristics, the initial management, overall survival (OS) and hospitalisations of patients with mBC before 2018 when immunotherapy for mBC was introduced in Norway.
Material and methods: It is a nationwide population-based study of primary mBC patients (diagnosed 2008-16). Descriptive statistics were applied and stratified for four initial management options (≤150 days after BC diagnosis): chemotherapy, major local treatment (cystectomy/pelvic radiotherapy), multimodal treatment (chemotherapy and local) and no anti-cancer treatment beyond transurethral resection of bladder tumour (untreated). Group differences were evaluated by Chi-square and Kruskal–Wallis test; OS was estimated with Kaplan–Meier.
Results: Of the 305 patients included, 76 (25%) patients had chemotherapy, 46 (15%) patients had major local treatment, 21 (7%) patients had multimodal treatment and 162 (53%) patients were untreated. Median OS ranged from 2.3 months (untreated) to 9.8 months (chemotherapy). Patients who received treatment had a higher rate of hospitalisation, with a median stay of three to four times that of untreated patients.
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.
Downloads
References
Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244–58. https://doi.org/10.1016/j.annonc.2021.11.012 DOI: https://doi.org/10.1016/j.annonc.2021.11.012
Witjes JA, Cathomas R, Compérat E, et al. The EAU Guidelines on Muscle-invasive and Metastatic bladder cancer 2022. [Accessed Aug, 2022] Available from: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77. https://doi.org/10.1200/JCO.2000.18.17.3068 DOI: https://doi.org/10.1200/JCO.2000.18.17.3068
Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15(7):2564–9. https://doi.org/10.1200/JCO.1997.15.7.2564 DOI: https://doi.org/10.1200/JCO.1997.15.7.2564
von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8. https://doi.org/10.1200/JCO.2005.07.757 DOI: https://doi.org/10.1200/JCO.2005.07.757
Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer ‘unfit’ for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8. https://doi.org/10.1200/JCO.2011.34.8433 DOI: https://doi.org/10.1200/JCO.2011.34.8433
Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3): 506–13. https://doi.org/10.1002/cncr.22031 DOI: https://doi.org/10.1002/cncr.22031
De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer ‘unfit’ for cisplatin-based chemotherapy: phase II – results of EORTC study 30986. J Clin Oncol. 2009;27(33):5634–9. https://doi.org/10.1200/JCO.2008.21.4924 DOI: https://doi.org/10.1200/JCO.2008.21.4924
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMoa1613683 DOI: https://doi.org/10.1056/NEJMoa1613683
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/S0140-6736(16)00561-4 DOI: https://doi.org/10.1016/S0140-6736(16)00561-4
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3): 312–22. https://doi.org/10.1016/S1470-2045(17)30065-7 DOI: https://doi.org/10.1016/S1470-2045(17)30065-7
Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788 DOI: https://doi.org/10.1056/NEJMoa2002788
Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600. https://doi.org/10.1200/JCO.19.01140 DOI: https://doi.org/10.1200/JCO.19.01140
Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35. https://doi.org/10.1056/NEJMoa2035807 DOI: https://doi.org/10.1056/NEJMoa2035807
Cancer in Norway 2021 – cancer incidence, mortality, survival and prevalence in Norway [Internet]. Oslo: Cancer Registry of Norway; 2022. [Cited Aug, 2022] Available from: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2021/cin_report.pdf [cited 2022].
Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølgning av blærekreft Oslo: Helsedirektoratet; 2013. Available from: https://blaerekreft.no/wp-content/uploads/Nasjonalt-handlingsprogram-bl%C3%A6rekreft.pdf [cited 3 August 2021].
Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av blære- og urotelkreft 2021. [Cited Aug, 2022] Available from: https://www.helsedirektoratet.no/produkter?tema=retningslinje
Flannery K, Cao X, He J, et al. Survival rates and health care costs for patients with advanced bladder cancer treated and untreated with chemotherapy. Clin Genitourin Cancer. 2018;16(4):e909–17. https://doi.org/10.1016/j.clgc.2018.03.002 DOI: https://doi.org/10.1016/j.clgc.2018.03.002
Richters A, Mehra N, Meijer RP, et al. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study. Cancer Treat Res Commun. 2020;25:100266. https://doi.org/10.1016/j.ctarc.2020.100266 DOI: https://doi.org/10.1016/j.ctarc.2020.100266
Galsky MD, Pal SK, Lin SW, et al. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the united states. Bladder Cancer. 2018;4(2):227–38. https://doi.org/10.3233/BLC-170149 DOI: https://doi.org/10.3233/BLC-170149
Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31. https://doi.org/10.1016/j.ejca.2008.10.037 DOI: https://doi.org/10.1016/j.ejca.2008.10.037
Bakken IJ, Ariansen AMS, Knudsen GP, et al. The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: research potential of two nationwide health-care registries. Scand J Public Health. 2019;48(1):49–55. https://doi.org/10.1177/1403494819859737 DOI: https://doi.org/10.1177/1403494819859737
Nasjonal tjeneste for validering og dekningsgradsanalyser – Årsrapporter: Helsedirektoratet. [Cited Sep, 2022] Available from: https://www.helsedirektoratet.no/rapporter/nasjonal-tjeneste-for-validering-og-dekningsgradsanalyser-og-arsrapport.
Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13. https://doi.org/10.1200/JCO.2011.38.6979 DOI: https://doi.org/10.1200/JCO.2011.38.6979
Veskimäe E, Espinos EL, Bruins HM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European association of urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncolgy. 2019;2(6):625–42. https://doi.org/10.1016/j.euo.2019.09.003 DOI: https://doi.org/10.1016/j.euo.2019.09.003
Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81. https://doi.org/10.1200/JCO.1999.17.10.3173 DOI: https://doi.org/10.1200/JCO.1999.17.10.3173
Reesink DJ, van de Garde EMW, Peters BJM, et al. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci Rep. 2020;10(1):15822. https://doi.org/10.1038/s41598-020-72820-y DOI: https://doi.org/10.1038/s41598-020-72820-y
Omland LH, Lindberg H, Carus A, et al. Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study. Eur Urol Open Sci. 2021;24:1–8. https://doi.org/10.1016/j.euros.2020.12.002 DOI: https://doi.org/10.1016/j.euros.2020.12.002
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Christina Tanem Møller, Gunnar Tafjord, Augun Blindheim, Viktor Berge, Sophie Fosså, Bettina Kulle Andreassen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
